Publications by authors named "M Wainszelbaum"
Article Synopsis
- Camonsertib is an oral drug targeting ATR kinase, showing effectiveness in tumors with DNA damage issues, but often causes anemia as a side effect.
- The TRESR study tested three dosing regimens to evaluate long-term safety and effectiveness, focusing on anemia rates and overall tumor response.
- Results showed that the 160mg QD for 2 weeks on and 1 week off regimen significantly reduced severe anemia risk without affecting the drug's cancer-fighting ability, making it the preferred dosing schedule for future studies.
Article Synopsis
- Predictive biomarkers are important for guiding targeted cancer treatments, and the ATR inhibitor camonsertib shows promise for tumors with specific DNA damage response gene alterations.
- In a phase 1 trial involving 120 patients with advanced solid tumors, camonsertib demonstrated good tolerance, with the most common side effect being anemia.
- Preliminary results showed a recommended phase 2 dose of 160 mg weekly, with some patients experiencing clinical and molecular responses, particularly those with ovarian cancer and specific genetic alterations.
The ErbB family of receptor tyrosine kinases comprises four members: epidermal growth factor receptor (EGFR/ErbB1), human EGFR 2 (HER2/ErbB2), ErbB3/HER3, and ErbB4/HER4. The first two members of this family, EGFR and HER2, have been implicated in tumorigenesis and cancer progression for several decades, and numerous drugs have now been approved that target these two proteins. Less attention, however, has been paid to the role of this family in mediating cancer cell survival and drug tolerance.
View Article and Find Full Text PDFExpression of the hominoid-specific TBC1D3 oncoprotein enhances growth factor receptor signaling and subsequently promotes cellular proliferation and survival. Here we report that TBC1D3 is degraded in response to growth factor signaling, suggesting that TBC1D3 expression is regulated by a growth factor-driven negative feedback loop. To gain a better understanding of how TBC1D3 is regulated, we studied the effects of growth factor receptor signaling on TBC1D3 post-translational processing and turnover.
View Article and Find Full Text PDFInsulin/IGF-1 signaling plays a pivotal role in the regulation of cellular homeostasis through its control of glucose metabolism as well as due to its effects on cell proliferation. Aberrant regulation of insulin signaling has been repeatedly implicated in uncontrolled cell growth and malignant transformations. TBC1D3 is a hominoid specific gene previously identified as an oncogene in breast and prostate cancers.
View Article and Find Full Text PDF